Last €104.96 EUR
Change Today -0.81 / -0.76%
Volume 0.0
SIQ On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 6:04 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

sigma-aldrich (SIQ) Snapshot

Open
€105.36
Previous Close
€105.77
Day High
€105.48
Day Low
€104.96
52 Week High
09/22/14 - €109.00
52 Week Low
10/22/13 - €60.78
Market Cap
12.5B
Average Volume 10 Days
35.2
EPS TTM
--
Shares Outstanding
119.0M
EX-Date
08/27/14
P/E TM
--
Dividend
€0.89
Dividend Yield
0.64%
Current Stock Chart for SIGMA-ALDRICH (SIQ)

sigma-aldrich (SIQ) Related Businessweek News

No Related Businessweek News Found

sigma-aldrich (SIQ) Details

Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment worldwide. Its chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and diagnosis of disease; and as key components in pharmaceutical, diagnostics, and high technology manufacturing. The company sells its products to commercial laboratories, pharmaceutical companies, industrial companies, universities, diagnostics companies, biotechnology companies, electronics companies, hospitals, governmental institutions, and non-profit organizations. Sigma-Aldrich Corporation was founded in 1951 and is based in St. Louis, Missouri.

9,000 Employees
Last Reported Date: 07/24/14
Founded in 1951

sigma-aldrich (SIQ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $876.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $465.4K
Executive Vice President and President of App...
Total Annual Compensation: $437.7K
Executive Vice President and President of SAF...
Total Annual Compensation: $386.5K
Executive Vice President and President of Res...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

sigma-aldrich (SIQ) Key Developments

Sigma-Aldrich Expands the Ascentis® Express U/UHPLC Column Line with Addition of 2.0 Micron Fused Core® Particle Columns

Sigma-Aldrich Corporation announced that Supelco, its innovative analytical products and services research business, has launched the Ascentis(®) Express 2.0 micron, a high-speed, ultra high-performance liquid chromatography (UHPLC) column platform based on the proven Fused-Core(®) particle design. Ascentis Express 2.0 micron Fused-Core particles are designed to provide UHPLC performance, while addressing the disadvantages inherent in existing sub-2 micron UHPLC columns. Ascentis Express 2.0 UHPLC columns deliver 300,000 plates per meter efficiency. Furthermore, Ascentis Express 2.0 micron columns are less susceptible to column plugging due to the large 1.0 m frits on the column inlet. While Ascentis Express columns can be used up to 1,000 bar (14,500 psi), they will produce approximately 20% lower back pressure than most commercially available sub-2 m UHPLC columns under the same conditions, reducing concerns of column frictional heating and instrument wear and tear associated with very small particles.

Sigma-Aldrich Corporation Introduces Stable-Labeled Certified Reference Materials of Kratom Alkaloids

Sigma-Aldrich Corporation announced that the Cerilliant(R) brand within its Applied Diagnostics and Testing business segment now offers the first stable-labeled internal standards of the kratom alkaloids mitragynine and 7-hydroxymitragynine. These new solution Certified Reference Materials (CRMs) offer testing laboratories deuterium-labeled internal standards suitable for quantitation of mitragynine and 7-hydroxymitragynine levels in biological and plant-based samples using mass spectrometry-based methods. Mitragynine and 7-hydroxymitragynine are psychoactive alkaloids of the plant Mitragyna speciosa, commonly known as kratom. Kratom acts on u-opioid receptors and purportedly exhibits dose dependent effects, acting as a stimulant at low concentrations and an analgesic at high concentrations. Kratom possesses a high addiction potential and can reportedly cause adverse health effects such as seizures, hallucinations, and delusions.

Theralase Partners with Sigma-Aldrich Corporation in Manufacture of Anti Cancer Drugs

Theralase Technologies Inc. announced that it has collaborated with Sigma-Aldrich Corporation's custom manufacturing services business unit SAFC in the manufacture of the Photo Dynamic Compounds (PDCs) being developed by Theralase for the destruction of cancer. Under the terms of the agreement, SAFC will develop the Standard Operating Procedures (SOPs) to manufacture initial quantities of each of Theralase's four lead PDCs. Once Theralase selects the final lead PDC at the end of the fourth quarter 2014, SAFC will manufacture both a 100-gram pre-Good Manufacturing Practice (pre-GMP) batch and finally a 500-gram GMP batch of the PDC. This final 500-gram batch is intended to be suitable for final sterilization and packaging into individual patient doses for safety and efficacy evaluation through a Health Canada /FDA Phase I/IIa clinical trial, expected in early 2015. SAFC is Theralase's partner of choice to provide a continuous supply of the lead PDC for future clinical trials and eventually commercialization of the PDC for human bladder cancer applications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIQ:GR €104.96 EUR -0.81

SIQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 2,966 INR +47.65
Illumina Inc $164.91 USD 0.00
International Flavors & Fragrances Inc $95.41 USD 0.00
UCB SA €62.13 EUR -1.96
Westlake Chemical Corp $73.04 USD 0.00
View Industry Companies
 

Industry Analysis

SIQ

Industry Average

Valuation SIQ Industry Range
Price/Earnings 31.8x
Price/Sales 5.8x
Price/Book 5.2x
Price/Cash Flow 31.4x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGMA-ALDRICH, please visit www.sigmaaldrich.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.